PASG FY 2024 Earnings — Passage Bio, Inc. Revenue & Financial Results | Market Cap Arena

PASGPassage Bio, Inc.

$29M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$70M

Net Income

-$65M

EPS (Diluted)

$-21.44

Cash Flow

Operating Cash Flow

-$48M

Free Cash Flow

-$48M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$102M

Total Liabilities

$41M

Stockholders' Equity

$61M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$4M	+100.0%
Operating Income	-$70M	-$100M	+29.7%
Net Income	-$65M	-$102M	+36.5%